Biography
Dr. Maximilian Julvé is a clinical researcher specializing in solid tumor cellular therapies, with a focus on melanoma. His work has contributed to advancements in adoptive cell therapies, including tumor-infiltrating lymphocyte (TIL) treatments, and he has been involved in developing novel biomarkers to predict patient responses to immunotherapy. Julvé's research includes the creation of a granulocyte-based scoring system aimed at enhancing prognostic assessments for patients undergoing combination immunotherapy. His publications address various aspects of immuno-oncology, such as the management of immune-related toxicities and the development of innovative therapeutic strategies for melanoma.